Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy

被引：26

作者：

Bahrami, Afsane ^{[1
,2
]}

Amerizadeh, Forouzan ^{[1
,2
]}

Hassanian, Seyed Mahdi ^{[3
,4
]}

ShahidSales, Soodabeh ^{[5
]}

Khazaei, Majid ^{[6
]}

Maftouh, Mina ^{[3
]}

Ghayour-Mobarhan, Majid ^{[3
]}

Ferns, Gordon A. ^{[7
]}

Avan, Amir ^{[3
]}

机构：

[1] Mashhad Univ Med Sci, Fac Med, Dept Modern Sci & Technol, Mashhad, Iran

[2] Mashhad Univ Med Sci, Fac Med, Student Res Comm, Mashhad, Iran

[3] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Iran

[4] Mashhad Univ Med Sci, Dept Med Biochem, Fac Med, Mashhad, Iran

[5] Mashhad Univ Med Sci, Canc Res Ctr, Mashhad, Iran

[6] Mashhad Univ Med Sci, Fac Med, Dept Physiol, Mashhad, Iran

[7] Brighton & Sussex Med Sch, Div Med Educ, Brighton, Sussex, England

来源：

JOURNAL OF CELLULAR PHYSIOLOGY | 2018年 / 233卷 / 03期

关键词：

colorectal cancer; oxaliplatin; predictive biomarkers; resistance; DNA-REPAIR GENES; GLUTATHIONE-S-TRANSFERASE; GROWTH-FACTOR-RECEPTOR; MICROSATELLITE INSTABILITY; ADJUVANT CHEMOTHERAPY; CHROMOSOMAL INSTABILITY; THERAPEUTIC PROGNOSIS; FOLFOX-4; CHEMOTHERAPY; CISPLATIN RESISTANCE; CHINESE POPULATION;

D O I：

10.1002/jcp.25966

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Chemotherapy regimen containing oxaliplatin is often the first-line treatment for patient with advanced colorectal cancer. Oxaliplatin binds to DNA, leading to the formation of crosslinks and bulky adducts. Approximately 50% of patients with CRC benefit from treatment with oxaliplatin. It is possible that genetic variants in biological pathways involved in drug transportation, drug metabolism, DNA damage repair, and cell cycle modulation might affect the activity, or efficacy of oxaliplatin. Because oxaliplatin resistance may be related to these genetic variants and may therefore be an important reason for treatment failure, we have summarized the genetic variations that have been reported to be predictive markers of the response to oxaliplatin based therapy in patients with advanced CRC.

引用

页码：2193 / 2201

页数：9

共 50 条

[21] Advanced colorectal cancer (ACRC) in elderly patients: Evaluation of three different oxaliplatin-based chemotherapy regimens
Pinto, Carmine
Di Fabio, Francesca
Gentile, Anna Lisa
Mini, Enrico
Giaquinta, Stefania
Llimpe, Fabiola Lorena Rojas
Mutri, Vita
Piana, Edera
Mazzei, Teresita
Martoni, Andrea
ANNALS OF ONCOLOGY, 2005, 16 : 47 - 47
[22] Role of Calcium/Magnesium Infusion in Oxaliplatin-Based Chemotherapy for Colorectal Cancer Patients
Kurniali, Peter C.
Luo, Lu Guang
Weitberg, Alan B.
ONCOLOGY-NEW YORK, 2010, 24 (03): : 289 - 292
[23] Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC)
Berretta, Massimiliano
Zanet, Ernesto
Nasti, Guglielmo
Lleshi, Arben
Frustaci, Sergio
Fiorica, Francesco
Bearz, Alessandra
Talamini, Renato
Lestuzzi, Chiara
Lazzarini, Renzo
Fisichella, Rossella
Cannizzaro, Renato
Iaffaioli, Rosario Vincenzo
Berretta, Salvatore
Tirelli, Umberto
ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2012, 55 (02) : 271 - 275
[24] Genetic variants in DNA repair genes and survival in colorectal cancer patients treated with oxaliplatin combination chemotherapy
Kap, E. J.
Seibold, P.
Buck, K.
Benner, A.
Hoffmeister, M.
Brenner, H.
Ulrich, C. M.
Burwinkel, B.
Chang-Claude, J.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S496 - S496
[25] Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer
Moosmann, Nicolas
Heinemann, Volker
EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (03) : 319 - 329
[26] Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients
Park, Hanla A.
Edelmann, Dominic
Canzian, Federico
Seibold, Petra
Harrison, Tabitha A.
Hua, Xinwei
Shi, Qian
Silverman, Allison
Benner, Axel
Macauda, Angelica
Schneider, Martin
Goldberg, Richard M.
Alberts, Steven R.
Hoffmeister, Michael
Brenner, Hermann
Chan, Andrew T.
Peters, Ulrike
Newcomb, Polly A.
Chang-Claude, Jenny
INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (09) : 1623 - 1634
[27] Neutropenia in colorectal cancer treated with oxaliplatin-based hyperthermic intraperitoneal chemotherapy: An observational cohort study
Peter H Cashin
Lana Ghanipour
Malin Enblad
David L Morris
World Journal of Gastrointestinal Oncology, 2020, (05) : 549 - 558
[28] Neutropenia in colorectal cancer treated with oxaliplatin-based hyperthermic intraperitoneal chemotherapy: An observational cohort study
Cashin, Peter H.
Ghanipour, Lana
Enblad, Malin
Morris, David L.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 12 (05) : 549 - 558
[29] Inflammatory cytokines and toxic effects of oxaliplatin-based chemotherapy in patients with colorectal cancer.
Wang, X. S.
Cleeland, C. S.
Johnson, V. E.
Reuben, J. M.
Fogelman, D. R.
Malekifar, M.
Liao, K. E.
Liu, P.
Cohen, E. N.
Gilmore, K. R.
Eng, C.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[30] Impact of Oxaliplatin-based chemotherapy on the haemoglobin levels: A retrospective analysis in patients with colorectal cancer
Queralt, Bernardo
Juez, Ignacio
Hernandez, Xavier
Vinas, Gemma
Rubio, Jordi
Soler, Francesc
Monleon, Antonio
Colomer, Ramon
ANNALS OF ONCOLOGY, 2004, 15 : 86 - 86

← 1 2 3 4 5 →